ROCKWELL MEDICAL, INC. Annual Report - How They Did This Year

I’ve put together this guide to help you understand how Rockwell Medical (RMTI) performed this year. My goal is to turn complex filings into plain English so you can decide if this company fits your investment strategy.

1. What does this company do?

Rockwell Medical acts as a vital supplier for dialysis centers. They make the liquid and dry concentrates that keep dialysis machines running for patients with kidney failure. They operate a national network of manufacturing and distribution facilities. Beyond concentrates, they sell supplies like blood tubing and needles, acting as a "one-stop-shop" for clinics.

2. Recent Business Highlights

Rockwell is currently focused on growth and diversification. In 2025, they made several moves to stabilize their future:

• Customer Diversification: They reduced their reliance on their largest customer, DaVita, which previously provided nearly half of their revenue. To offset this, they added 30 new customers in the western U.S. and signed a multi-year deal with Innovative Renal Care.
• Operational Overhaul: They closed their South Carolina facility in August 2025 to improve profit margins. By outsourcing logistics, they cut annual operating expenses by $2.1 million.
• Product Innovation: In February 2025, they launched a new FDA-approved bicarbonate cartridge. This product targets a $150 million market and offers higher profit margins than their traditional bulk liquids.

3. Financial Health & Market Position

Rockwell is a small company with a market value of about $28.7 million. As of late 2025, they held $25 million in cash. While they aren't consistently profitable yet, they significantly improved their cash flow, using only $0.7 million for operations compared to $8.4 million the year before. Revenue for the year totaled $82.3 million.

However, they carry an $8.8 million loan with strict rules. If they fail to meet specific financial targets, the lender can demand immediate repayment of the entire loan.

4. Major Risks

• The "Debt Trap": Their loan agreement limits how they spend money. They cannot take on more debt, pay dividends, or make large investments without lender approval. If cash runs low, they may issue more shares, which reduces your ownership percentage.
• The "Price Squeeze": Raw material costs rose 6% in 2025. Because many of their contracts have fixed prices, they cannot easily pass these higher costs on to customers.
• Regulatory Hurdles: The FDA requires strict oversight. A 2025 inspection of their Michigan plant required $0.5 million in immediate upgrades. Any future issues could halt production, which would be devastating.
• Uncertain Future: Management believes they have enough cash to last through 2026. However, they lack a clear path to long-term profit without significant revenue growth.

5. Future Outlook

Management is "right-sizing" the business. Their success depends on automating production to lower costs by 12% and growing their new customer base. Their primary goal for 2026 is to reach positive earnings by selling more high-margin cartridges while keeping costs low.

My take: Rockwell is a high-risk turnaround play. They’ve cut costs and diversified, but they are still walking a tightrope with their debt and limited cash. Before investing, consider whether you believe their new product line and operational efficiencies can outpace their current debt obligations and rising material costs.